Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Glioblastoma 23Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 17Rectal Neoplasms 13Prostatic Neoplasms 13Gliosarcoma 12Lung Neoplasms 10Head and Neck Neoplasms 10Esophageal Neoplasms 10Brain Neoplasms 10Neoplasms 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Adenocarcinoma Of Esophagus 8Sarcoma 7Neoplasm Metastasis 7Central Nervous System Neoplasms 7Pancreatic Neoplasms 6Melanoma 6Glioma 6Carcinoma, Squamous Cell 6Astrocytoma 6Urinary Bladder Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Oropharyngeal Neoplasms 4Medulloblastoma 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4

Interventions

temsirolimus 1ganitumab 1efineptakin alfa 1Vinorelbine 1Vincristine 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Radiotherapy 1Radiation 1Irinotecan 1Dasatinib 1Dactinomycin 1Cyclophosphamide 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma, Alveolar × Radiation × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡